29C1 Stock Chart & Stats
€2.08
€0.08(3.85%)
At close: 4:00 PM EDT
€2.08
€0.08(3.85%)
Day’s Range― - ―
52-Week Range€1.76 - €2.46
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€142.35M
Enterprise Value€291.62
Total Cash (Recent Filing)€10.05M
Total Debt (Recent Filing)€76.33M
Price to Earnings (P/E)8.5
Beta0.16
Next Earnings
Nov 11, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.42
Shares Outstanding63,514,038
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)2.19
Price to Sales (P/S)0.65
P/FCF Ratio10.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.25Price Target Upside56.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.09
Revenue Forecast (FY)€238.23M
Bulls Say, Bears Say
Bulls Say
Return To Profitability & Revenue GrowthCareRx has moved from multi-year losses to sustained TTM profitability with meaningful top-line expansion. Durable earnings reduce insolvency risk, provide room for reinvestment in logistics/clinical services, and improve capacity to absorb cyclical care-home occupancy swings over the next 2–6 months.
Strong Free Cash Flow GenerationHigh FCF and strong conversion of earnings into cash support sustainable dividend payments, ongoing site rationalization, and targeted bed onboarding without immediate external funding. Robust cash conversion indicates earnings quality and less reliance on financing for near-term operational needs.
Material Contract Win And Growth PipelineA large national contract plus an explicit organic bed-addition target build recurring prescription volumes and scale benefits in distribution and clinical services. This improves long-term revenue visibility and supports margin accretion as onboarding completes and utilization rises over subsequent quarters.
Bears Say
Thin Operating MarginsNarrow operating margins leave limited buffer versus cost inflation, funding cuts, or volume dips. With modest operating leverage, small adverse changes in payer fees or labor/transport costs can materially compress profitability and cash flow, increasing earnings volatility over months.
Exposure To Provincial Funding ChangesRevenue dependence on provincially governed funding schedules creates structural policy risk. The Ontario ward‑bed change is a multi-quarter hit tied to redevelopment timing, showing that government funding shifts can produce sustained revenue gaps until policy or physical assets change.
Liquidity And Leverage VariabilityAlthough leverage improved vs. prior years, recent cash depletion and a QoQ net debt increase highlight sensitivity to working capital, capex and timing of collections. This variability can constrain flexibility for M&A, larger capex, or buffer against further funding shocks in the medium term.
CareRx News
29C1 FAQ
What was CareRx’s price range in the past 12 months?
CareRx lowest stock price was €1.76 and its highest was €2.46 in the past 12 months.
What is CareRx’s market cap?
CareRx’s market cap is €142.35M.
When is CareRx’s upcoming earnings report date?
CareRx’s upcoming earnings report date is Nov 11, 2026 which is in 98 days.
How were CareRx’s earnings last quarter?
CareRx released its earnings results on Jul 29, 2026. The company reported €0.006 earnings per share for the quarter, missing the consensus estimate of €0.014 by -€0.008.
Is CareRx overvalued?
According to Wall Street analysts CareRx’s price is currently Undervalued.
Does CareRx pay dividends?
CareRx does not currently pay dividends.
What is CareRx’s EPS estimate?
CareRx’s EPS estimate is 0.02.
How many shares outstanding does CareRx have?
CareRx has 63,514,038 shares outstanding.
What happened to CareRx’s price movement after its last earnings report?
CareRx reported an EPS of €0.006 in its last earnings report, missing expectations of €0.014. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of CareRx?
Currently, no hedge funds are holding shares in DE:29C1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CareRx Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€3.25 (56.06% Upside)
€3.25 (56.06% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
68.12%
12-Months-Change
Fundamentals
Return on Equity
2.18%
Trailing 12-Months
Asset Growth
11.38%
Trailing 12-Months
Company Description
CareRx
CareRx Corporation, operating with its subsidiaries, specializes in delivering tailored pharmaceutical services to Canada's senior demographic. The company manages a vast network of medication dispensing facilities, which are responsible for providing chronic prescriptions and a variety of other advanced clinical pharmacy solutions. Currently, it caters to approximately 50,000 individuals residing in roughly 900 distinct senior and communal living environments, including extended care residences, retirement communities, supportive living facilities, and group homes. Founded in 2001 and based in Toronto, Canada, the corporation rebranded as CareRx Corporation in June 2020, having formerly been known as Centric Health Corporation.
29C1 Stock 12 Month Forecast
Average Price Target
€3.25
▲(56.06% Upside)
Technical Analysis
Extendicare
―
Nova Leap Health
―
Sienna Senior Living
―
Medical Facilities
―
WELL Health Technologies Corp
―